Parkville, New South Wales, Australia CSL is the famous Corporate Investor, which was founded in 1916. The leading representative office of defined Corporate Investor is situated in the Parkville. The venture was found in Australia.
The usual things for fund are deals in the range of 5 - 10 millions dollars. The important activity for fund was in 2000. The fund is generally included in less than 2 deals every year.
Among the most popular portfolio startups of the fund, we may highlight eBioinformatics. We can highlight the next thriving fund investment areas, such as Information Services, Biotechnology. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 1 and less years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 4-5 partakers. The meaningful sponsors for the fund in investment in the same round are Rothschild Australian Bioscience Trust, Medical Research Commercialisation Fund (MRCF), International Biotechnology Trust.
Related Funds
| Fund Name | Location |
| Altonomy | Central Region, Singapore, Singapore |
| Arnel Capital Management | - |
| Atop Capital | - |
| Beijing Runda Huanke Investment | Beijing, Beijing, China |
| Bespoke Strategies | - |
| Bios Partners | Fort Worth, Texas, United States |
| CF Capital Management | Connecticut, Stamford, United States |
| Feizhu Zichan | - |
| Ginko Ventures | Geneva, Geneve, Switzerland |
| Grofers International | Central, Central Region, Singapore |
| Hillcrest Management | Milford, New Hampshire, United States |
| imGO | Kyongsang-bukto, South Korea, Yongchon |
| Levy Restaurants | Chicago, Illinois, United States |
| Owl Rock Capital Partners | New York, New York, United States |
| Regenerative Medicine Minnesota | Minnesota, Minnesota City, United States |
| The Yield Lab | Missouri, St Louis, United States |
| Three Six Zero | California, Los Angeles, United States |
| Xinmei Asset | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ena Respiratory | $8M | 28 Sep 2020 | Victoria | ||
Denteric | $10M | 25 Sep 2019 | Melbourne, Victoria, Australia |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ena Respiratory | $8M | 28 Sep 2020 | Victoria | ||
Denteric | $10M | 25 Sep 2019 | Melbourne, Victoria, Australia |
